Omeros Q4 Earnings Call Highlights

Chronological Source Flow
Back

AI Fusion Summary

Omeros' Q4 2025 earnings call highlighted a $240 million upfront asset sale and license deal with Novo Nordisk for zaltenibart, plus FDA approval of narsoplimab (YARTEMLEA) for transplant‑associated thrombotic microangiopathy, marking a turning point.
02/04 10:03 defenseworld.net
4 Πηγές
02/04 11:26 defenseworld.net
02/04 11:26 defenseworld.net
02/04 11:26 defenseworld.net
Comments
Loading...
0